Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients-Reference-Cited by-同舟云学术

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients

Published:2021-03 Issue: Volume:Volume 14 Page:2139-2148
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Hsu Kuo-Hsuan^ORCID,Huang Jing-Wen^ORCID,Tseng Jeng-Sen,Chen Kuan-Wen,Weng Yih-Chyang,Yu Sung-Liang,Yang Tsung-Ying,Huang Yen-Hsiang,Chen Jeremy JW,Chen Kun-Chieh,Chang Gee-Chen

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference43 articles.

1. Cancer statistics, 2020

2. Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

3. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

4. EGFR testing in lung cancer is ready for prime time

5. EGFR testing in lung cancer is ready for prime time

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional local therapy before disease progression for EGFR-mutated advanced lung cancer: a systematic review and meta-analysis;Translational Lung Cancer Research;2024-03

2. Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib;Therapeutic Advances in Medical Oncology;2024-01

3. Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis;International Journal of Surgery;2023-03-28

4. A novel tool to evaluate and quantify radiation pneumonitis: A retrospective analysis of correlation of dosimetric parameters with volume of pneumonia patch;Frontiers in Oncology;2023-03-13

5. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium;The Lancet Oncology;2023-03